PMID- 17563907
OWN - NLM
STAT- MEDLINE
DCOM- 20080124
LR  - 20220408
IS  - 1043-3074 (Print)
IS  - 1043-3074 (Linking)
VI  - 29
IP  - 10
DP  - 2007 Oct
TI  - Salivary duct carcinoma: a clinical and histologic review with implications for 
      trastuzumab therapy.
PG  - 907-12
AB  - BACKGROUND: Salivary duct carcinoma (SDC) is an aggressive tumor of the head and 
      neck with a poor prognosis. The objective was to study SDC and recommend the use 
      of trastuzumab as adjuvant therapy. METHODS: A retrospective chart review of 
      patients seen between 1993 and 2006 was performed. Tumor specimens were examined 
      for HER-2 protein overexpression via immunohistochemistry (IHC) and fluorescence 
      in situ hybridization (FISH) methods. RESULTS: Of the 7 patients with SDC, 57% 
      had tumors arising in the parotid gland, the majority having facial nerve 
      paralysis, 71% with nodal disease, and 43% having recurrence. All samples were 
      HER-2 positive on IHC. Three patients had FISH-positive tumors, recurrent 
      disease, and received trastuzumab therapy; 1 of the 3 died after 20 months and a 
      second has shown disappearance of metastatic disease. CONCLUSIONS: Trastuzumab is 
      effective in treating HER-2-positive breast cancer. Given immunohistochemical 
      similarities between SDC and ductal carcinoma of the breast, patients with 
      FISH-positive HER-2/neu SDC should be considered for trastuzumab therapy.
FAU - Nabili, Vishad
AU  - Nabili V
AD  - Division of Head and Neck Surgery, Department of Surgery, David Geffen School of 
      Medicine at UCLA, 10833 LeConte Avenue, Los Angeles, California 90095, USA.
FAU - Tan, Jesse W
AU  - Tan JW
FAU - Bhuta, Sunita
AU  - Bhuta S
FAU - Sercarz, Joel A
AU  - Sercarz JA
FAU - Head, Christian S
AU  - Head CS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - BG3F62OND5 (Carboplatin)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Ductal/metabolism/mortality/therapy
MH  - Carcinoma, Intraductal, Noninfiltrating/metabolism/mortality/therapy
MH  - Chemotherapy, Adjuvant
MH  - Facial Paralysis/etiology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/mortality/*therapy
MH  - Paclitaxel/administration & dosage
MH  - Radiotherapy, Adjuvant
MH  - Receptor, ErbB-2/metabolism
MH  - Retrospective Studies
MH  - Salivary Gland Neoplasms/metabolism/mortality/*therapy
MH  - Trastuzumab
EDAT- 2007/06/15 09:00
MHDA- 2008/01/25 09:00
CRDT- 2007/06/15 09:00
PHST- 2007/06/15 09:00 [pubmed]
PHST- 2008/01/25 09:00 [medline]
PHST- 2007/06/15 09:00 [entrez]
AID - 10.1002/hed.20614 [doi]
PST - ppublish
SO  - Head Neck. 2007 Oct;29(10):907-12. doi: 10.1002/hed.20614.